Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Navari, Rudolph M ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b South Bend Medical Services Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; OLANZAPINE; SEROTONIN 3 ANTAGONIST;

ACUTE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; ANTICIPATORY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; BREAKTHROUGH CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DELAYED CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; HUMAN; MEDICAL DECISION MAKING; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; REVIEW; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); NAUSEA; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NAUSEA; VOMITING;

EID: 84941712161     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/595894     Document Type: Review

References (46)

1. B. Bloechl-Daum, R. R. Deuson, P. Mavros, M. Hansen, and J. Herrstedt, "Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment," Journal of Clinical Oncology, vol. 24, no. 27, pp. 4472-4478, 2006.
2. L. Cohen, C. A. De Moor, P. Eisenberg, E. E. Ming, and H. Hu, "Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings," Supportive Care in Cancer, vol. 15, no. 5, pp. 497-503, 2007.
3. R. M. Navari, "Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents," Drugs, vol. 73, no. 3, pp. 249-262, 2013.
4. R. M. Navari, "Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer," Future Oncology, vol. 6, no. 7, pp. 1073-1084, 2010.
5. R. Navari, "The current status of the use of palonosetron," Expert Opinion on Pharmacotherapy, vol. 14, no. 10, pp. 1281-1284, 2013.
6. M. P. Curran and D. M. Robinson, "Aprepitant: a review of its use in the prevention of nausea and vomiting," Drugs, vol. 69, no. 13, pp. 1853-1878, 2009.
7. R. M. Navari, "Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting," European Journal of Pharmacology, vol. 722, no. 1,pp. 180-186, 2014.
8. L. Tan, J. Liu, X. Liu et al., "Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting," Journal of Experimental & Clinical Cancer Research, vol. 28, article 131, 2009.
9. R. M. Navari, S. E. Gray, and A. C. Kerr, "Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial," Journal of Supportive Oncology, vol. 9, no. 5, pp. 188-195, 2011.
10. R. M. Navari, "Treatment of chemotherapy-induced nausea," Community Oncology, vol. 9, no. 1, pp. 20-26, 2012.
11. R. M. Stern, K. L. Koch, and P. L. R. Andrews, Eds., Nausea: Mechanisms and Management, Oxford University Press, New York, NY, USA, 2011.
12. F. Roila, J. Herrstedt, M. Aapro et al., "Guideline update for MASCC and ESMO in the prevention of chemotherapyand radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference," Annals of Oncology, vol. 21, no. 5, pp. v232-v243, 2010.
13. E. Basch,A.A. Prestrud, P. J.Hesketh et al., "Antiemetics: American Society of Clinical Oncology clinical practice guideline update," Journal of Clinical Oncology, vol. 29, no. 31, pp. 4189-4198, 2011.
14. National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology Version 2.2014: Antiemesis, National Comprehensive Cancer Network (NCCN), 2014, http://www.nccn.org/professionals/physician gls/PDF/ antiemesis.pdf.
15. R. M. Navari, "Overview of the updated antiemetic guidelines for chemotherapy-induced nausea and vomiting," Community Oncology, vol. 4, no. 4, supplement 1, pp. 3S-11S, 2007.
16. L. Cohen, C. A. de Moor, P. Eisenberg, E. E. Ming, and H. Hu, "Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings," Supportive Care in Cancer, vol. 15, no. 5, pp. 497-503, 2007.
17. Y. C. T. Shih, Y. Xu, and L. S. Elting, "Costs of uncontrolled chemotherapy-induced nausea and vomiting among workingage cancer patients receiving highly or moderately emetogenic chemotherapy," Cancer, vol. 110, no. 3, pp. 678-685, 2007.
18. S. M. Grunberg, R. R. Deuson, P. Mavros et al., "Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality," Cancer, vol. 100, no. 10, pp. 2261-2268, 2004.
19. J. T. Hickok, J. A. Roscoe, G. R. Morrow, D. K. King, J. N. Atkins, and T. R. Fitch, "Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics," Cancer, vol. 97, no. 11, pp. 2880-2886, 2003.
20. M. G. Kris, "Why do we need another antiemetic? Just ask," Journal of ClinicalOncology, vol. 21,no. 22,pp. 4077-4080, 2003.
21. http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/ healthprofessional.
22. P. Hesketh, R. Navari, T. Grote et al., "Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer," Journal of Clinical Oncology, vol. 14, no. 8, pp. 2242-2249, 1996.
23. R. M. Navari, D. Gandara, P. J. Hesketh et al., "Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis," Journal of Clinical Oncology, vol. 13, no. 5, pp. 1242-1248, 1995.
24. F.Hulstaert, S. van Belle, H. Bleiberg et al., "Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting," Journal of Clinical Oncology, vol. 12, no. 11, pp. 2439-2446, 1994.
25. The Italian Group for Antiemetic Research, "Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy," The New England Journal ofMedicine, vol. 342, no. 21, pp. 1554-1559, 2000.
26. P. J.Hesketh, S.M. Grunberg, R. J. Gralla et al., "The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group," Journal of Clinical Oncology, vol. 21, no. 22, pp. 4112-4119, 2003.
27. J. M. Jones, R. Qin, A. Bardia, B. Linquist, S. Wolf, and C. L. Loprinzi, "Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy," Journal of Palliative Medicine, vol. 14, no. 7, pp. 810-814, 2011.
28. J. Bleicher, A. Bhaskara, T. Huyck et al., "Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials," Journal of Supportive Oncology, vol. 6, no. 1, pp. 27-32, 2008.
29. S. Chanthawong, S. Subongkot, and A. Sookprasert, "Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting," Journal of the Medical Association ofThailand, vol. 97, pp. 349-355, 2014.
30. R. M. Navari, C. K. Nagy, and S. E. Gray, "The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy," Supportive Care in Cancer, vol. 21, no. 6, pp. 1655-1663, 2013.
31. S. D. Passik, J. Lundberg, K. Kirsh et al., "A pilot exploration of the antiemetic activity of olanzapine (Zyprexa) for the relief of nausea in patients with advanced cancer and pain," Journal of Pain and Symptom Management, vol. 23, pp. 526-532, 2002.
32. W. F. Pirl and A. J. Roth, "Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report," Psycho-Oncology, vol. 9, no. 1, pp. 84-87, 2000.
33. W. C. Jackson and L. Tavernier, "Olanzapine for intractable nausea in palliative care patients," Journal of PalliativeMedicine, vol. 6, no. 2, pp. 251-255, 2003.
34. M. Srivastava, N. Brito-Dellan, M. P. Davis, M. Leach, and R. Lagman, "Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer," Journal of Pain and Symptom Management, vol. 25, no. 6, pp. 578-582, 2003.
35. F.P.Bymaster, D. O. Calligaro, J. F. Falcone et al., "Radioreceptor binding profile of the atypical antipsychotic olanzapine," Neuropsychopharmacology, vol. 14, no. 2, pp. 87-96, 1996.
36. F.P.Bymaster, J. F. Falcone, D. Bauzon et al., "Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine," European Journal of Pharmacology, vol. 430, no. 2-3, pp. 341-349, 2001.
37. J. A. Rudd, M. P. Ngan, M. K. Wai et al., "Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin,"Neuroscience Letters, vol. 392, no. 1-2,pp. 79-83, 2006.
38. K. Yakabi, C. Sadakane, M. Noguchi et al., "Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia," Endocrinology, vol. 151, no. 8, pp. 3773-3782, 2010.
39. R.M.Navari, L.H. Einhorn, S. D. Passik et al., "Aphase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study," Supportive Care in Cancer, vol. 13, no. 7, pp. 529-534, 2005.
40. R.M. Navari, L. H. Einhorn, P. J. Loehrer Sr. et al., "A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study," Supportive Care in Cancer, vol. 15, no. 11, pp. 1285-1291, 2007.
41. N.Mizukami,M. Yamauchi, K. Koike et al., "Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly ormoderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study," Journal of Pain and Symptom Management, vol. 47, no. 3, pp. 542-550, 2014.
42. X.-F.Wang, Y. Feng, Y.Chen, B. L. Gao, and B.-H.Han, "Ametaanalysis of olanzapine for the prevention of chemotherapyinduced nausea and vomiting," Scientific Reports, vol. 4, article 4813, 2014.
43. C. M. Hocking and G. Kichenadasse, "Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review," Supportive Care in Cancer, vol. 22, no. 4, pp. 1143-1151, 2014.
44. M.V. Bradford andA.Glode, "Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting," Journal of the Advanced Practitioner in Oncology, vol. 5, no. 1, pp. 24-29, 2014.
45. B. L. Rapoport, K. Jordan, J. A. Boice et al., "Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study," Supportive Care in Cancer, vol. 18, no. 4, pp. 423-431, 2010.
46. S. Vig, L. Seibert, and M. R. Green, "Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity," Journal of Cancer Research and Clinical Oncology, vol. 140, no. 1, pp. 77-82, 2014.